{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:09:02Z","timestamp":1774526942985,"version":"3.50.1"},"reference-count":41,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Medical Research Fund of the Samsung Medical Center","award":["SMO1151351"],"award-info":[{"award-number":["SMO1151351"]}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Recent data conflict on the clinical efficacy of later-generation fluoroquinolones, such as moxifloxacin or levofloxacin, for the treatment of multidrug-resistant tuberculosis (MDR-TB) that is resistant to ofloxacin but susceptible to moxifloxacin. The purpose of the present study was to evaluate whether later-generation fluoroquinolones can improve treatment outcomes in patients with ofloxacin-resistant, moxifloxacin-susceptible MDR-TB. A retrospective cohort study was performed on 208 patients with moxifloxacin-susceptible MDR-TB who were treated between 2006 and 2011. Later-generation fluoroquinolones were used for all patients. Overall, 171 patients (82%) had ofloxacin-susceptible, moxifloxacin-susceptible MDR-TB (ofloxacin-susceptible group), and 37 (18%) had ofloxacin-resistant, moxifloxacin-susceptible MDR-TB (ofloxacin-resistant group). Compared to the ofloxacin-susceptible group, the ofloxacin-resistant group was more likely to have a history of MDR-TB treatment (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.001) and cavitary lesions on chest radiography (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.001). In addition, the ofloxacin-resistant group was more likely than the ofloxacin-susceptible group to have resistance to the drugs pyrazinamide (\n            <jats:italic>P<\/jats:italic>\n            = 0.003), streptomycin (\n            <jats:italic>P<\/jats:italic>\n            = 0.015), prothionamide (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.001), and para-aminosalicylic acid (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.001). Favorable outcomes were more frequently achieved for the ofloxacin-susceptible group than for the ofloxacin-resistant group (91% [156\/171] versus 57% [21\/37], respectively [\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.001]). In multivariable regression logistic analysis, the ofloxacin-susceptible group was about 5.36 (95% confidence interval, 1.55 to 18.53) times more likely than the ofloxacin-resistant group (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.001) to have favorable outcomes. Despite\n            <jats:italic>in vitro<\/jats:italic>\n            moxifloxacin susceptibility, the frequency of favorable treatment outcomes for ofloxacin-resistant MDR-TB was significantly lower than that for ofloxacin-susceptible MDR-TB, even when later-generation fluoroquinolones were used, indicating that more-aggressive therapies may be needed for ofloxacin-resistant MDR-TB.\n          <\/jats:p>","DOI":"10.1128\/aac.01784-17","type":"journal-article","created":{"date-parts":[[2017,12,4]],"date-time":"2017-12-04T16:40:36Z","timestamp":1512405636000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":8,"title":["Limited Effect of Later-Generation Fluoroquinolones in the Treatment of Ofloxacin-Resistant and Moxifloxacin-Susceptible Multidrug-Resistant Tuberculosis"],"prefix":"10.1128","volume":"62","author":[{"given":"Hyun","family":"Lee","sequence":"first","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soohyun","family":"Ahn","sequence":"additional","affiliation":[{"name":"Statistics and Data Center, Research Institute for Future Medicine, Samsung Medical Center, Seoul, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na Young","family":"Hwang","sequence":"additional","affiliation":[{"name":"Statistics and Data Center, Research Institute for Future Medicine, Samsung Medical Center, Seoul, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyeongman","family":"Jeon","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O Jung","family":"Kwon","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee Jae","family":"Huh","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nam Yong","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Ki","family":"Kim","sequence":"additional","affiliation":[{"name":"Seoul Clinical Laboratories, Yongin, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won-Jung","family":"Koh","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(17)30079-6"},{"key":"e_1_3_2_3_2","volume-title":"World Health Organization","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. 2017. Global tuberculosis report 2017. World Health Organization, Geneva, Switzerland. http:\/\/www.who.int\/tb\/publications\/global_report\/en\/."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02308-2016"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2015.01.006"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.16.0117"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201303-0604OC"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201510-690BC"},{"key":"e_1_3_2_9_2","volume-title":"WHO\/HTM\/TB\/2016.04","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. 2016. WHO treatment guidelines for drug-resistant tuberculosis. WHO\/HTM\/TB\/2016.04. World Health Organization, Geneva, Switzerland. http:\/\/www.who.int\/tb\/areas-of-work\/drug-resistant-tb\/treatment\/resources\/en\/."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006914"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200911-1656OC"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00134712"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu619"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.14.0739"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2006.12.7"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks033"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.14.0814"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00968-10"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00506-13"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02583-13"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.124.4.1476"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1086\/653115"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.13.0307"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.14.0100"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00425-16"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx150"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2013.02.019"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00061-2017"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix422"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112433"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00598-2017"},{"key":"e_1_3_2_32_2","volume-title":"WHO\/HTM\/TB\/2014.11","author":"World Health Organization","year":"2014","unstructured":"World Health Organization. 2014. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. WHO\/HTM\/TB\/2014.11. World Health Organization, Geneva, Switzerland. http:\/\/www.who.int\/tb\/publications\/pmdt_companionhandbook\/en."},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv360"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw344"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2017.32.4.636"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02775-15"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01049-15"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04058-14"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv215"},{"key":"e_1_3_2_40_2","volume-title":"WHO\/HTM\/TB\/2008.392","author":"World Health Organization","year":"2008","unstructured":"World Health Organization. 2008. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. WHO\/HTM\/TB\/2008.392. World Health Organization, Geneva, Switzerland. http:\/\/www.who.int\/tb\/publications\/2008\/whohtmtb_2008_392\/en\/."},{"key":"e_1_3_2_41_2","volume-title":"Guidelines for the programmatic management of drug-resistant tuberculosis","author":"World Health Organization","year":"2008","unstructured":"World Health Organization. 2008. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. WHO\/HTM\/TB\/2008.402. World Health Organization, Geneva, Switzerland. http:\/\/whqlibdoc.who.int\/publications\/2008\/9789241547581_eng.pdf."},{"key":"e_1_3_2_42_2","volume-title":"WHO\/HTM\/TB\/2013.2","author":"World Health Organization","year":"2013","unstructured":"World Health Organization. 2013. Definitions and reporting framework for tuberculosis\u20142013 revision. WHO\/HTM\/TB\/2013.2. World Health Organization, Geneva, Switzerland. http:\/\/apps.who.int\/iris\/bitstream\/10665\/79199\/1\/9789241505345_eng.pdf."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01784-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01784-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:08:52Z","timestamp":1645477732000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01784-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1128\/AAC.01784-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.01784-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"2017-08-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-11-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01784-17"}}